Shineco subsidiary closes 51% acquisition of InfiniClone, files target financials

SHINECO, INC.

Shineco Life Science closed purchase of 51% equity in InfiniClone on June 18, 2025 from Dr. Lim Kah Meng.
InfiniClone had $23.15M total assets (FY2024), including $22.66M property & equipment, and net loss of $367K.
Consideration consisted of $380 share capital and $24.1M additional paid-in capital, valuing 51% at ~$24M.
InfiniClone focuses on iPSC technology for stem cell research, cosmeceuticals, and regenerative medicine.
Pro forma combined financials for nine months ended March 31, 2025 filed as Exhibit 99.3.

item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.